Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (BOLD-EXT)

NCT05426733 is registered in ClinicalTrials.gov with Albireo, an Ipsen Company as lead sponsor.

NCT NCT05426733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05426733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (BOLD-EXT)
Lead sponsor
Albireo, an Ipsen Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 5, 2022
Completion date
October 28, 2026
Enrollment
180 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

biliary atresia